Roche has raised its financial forecast for 2015 and announced plans to increase its Swiss franc dividend following solid growth of its pharmaceutical business in the first nine months, led by the CD20 antibody rituximab (MabThera/Rituxan). ---Subscribe to MedNous to access this article--- Company News
